AltheaDx

We are a commercial stage molecular diagnostics company specializing in the field of pharmacogenetics, or PGx. IDgenetix, our PGx product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain.

In addition to IDgenetix, AltheaDx provides gold standard, and innovative Research Services to global pharmaceutical, biotech and medical devices companies. We specialize in oncology, biomarker discovery, assay development and qualification as well as bioinformatics, pipeline development and data transfer. Our services support pharma and biotech clients in their clinical development, regulatory submissions, as well as drug or product commericalization. We use our expertise in next-generation sequencing (NGS) and our computational biology and information technology capabilities to analyze subject samples from preclinical through clinical development. Since AltheaDx is technology and platform-agnostic, we also perform and recommend assays to clients that best suits their needs from discovery to regulatory submission. Our services yield a start-to-finish suite of tools focused on molecular biomarker discovery, assay development, assay validation and prospective/ retrospective clinical trial testing in support of diagnostic development and commercialization. Technologies include real-time PCR, cell-based assays, microarrays, multiplex PCR and NGS.

Our capabilities have enabled our clients to:

• accelerate clinical development timelines
  
• increase the likelihood of patient response by prospectively analyzing specimens to identify patients with certain genomic alterations for enrollment in clinical trials for targeted therapeutics;
  
• understand complex combinations of genomic alterations to facilitate development of diagnostic tests necessary for target therapeutics commercialization
  
• create opportunities for drug combination studies or new target discovery by identifying mechanisms of primary and acquired resistance; and
  
• improve clinical trial design by designing cutting edge assays to understand primary end points of clinical studies
  

To date, we have provided these services under paid agreements to 12 of the top 20 global pharmaceutical companies, many of which are the leaders in developing targeted therapies. We are currently validating a number of companion diagnostic test assays in late stage clinical trials. We also derive revenue from licensing fees.